000			03787nam a22004695i 4500
999			_c6193 _d6193
001			6193
003			ES-MaUEC
005			20201203160810.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			191011s2020 gw | s |||| 0|eng d
020			_a9783030264390
024	7		_a10.1007/978-3-030-26439-0 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRC270.3 _b.T86 2020 EB
245	0	0	_aTumor Liquid Biopsies _cedited by Florence Schaffner, Jean-Louis Merlin, Nikolas von Bubnoff.
250			_a1st ed. 2020.
264		1	_aCham _bSpringer International Publishing : _bImprint: Springer _c2020.
300			_a1 recurso en línea (VI, 368 páginas)
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_atext file _bPDF
490	0		_aRecent Results in Cancer Research _x0080-0015 _v215
490	0		_aMedicine (Springer-11650)
505	0		_aCirculating Tumor Cells: Pathophysiology of Tumor Cell Release into the Circulation and characterization of CTC -- CTC enrichment technologies -- Genotyping of CTC :example Lung cancer -- CTC in Breast Cancer: a clinical approach -- Circulating Tumor DNA: Pathophysiology of ctDNA Release into the Circulation and its characterization -- Enrichment and Analysis of ctDNA -- ctDNA in Lung Cancer -- ctDNA in Breast Cancer -- ctDNA in Colorectal Cancer -- Dynamic Treatment Stratification using ctDNA -- Circulating Tumor RNA: Noncoding Tumor RNAs: Pathophysiology of Release and Techniques of Detection -- Circulating miRNAs as Biomarker in Cancer -- Plasma Subcompartments as Source for Tumor derived Biomarkers: Exosomes and Vesicles as Biomarker in Cancer -- Quantitative proteomic Analysis of Plasma in Cancer.
520			_aThis book is a comprehensive guide to the techniques, clinical applications, and benefits of the different forms of liquid biopsy employed in patients with a variety of tumor types, including lung, breast and colorectal cancer. Offering detailed explanations, it discusses the how changes in tumors can be tracked using these cutting-edge technologies, which enable the detection and analysis of diverse circulating biomarkers: tumor cells, tumor DNA, tumor RNA (free or in exosomes), and fluid biomarkers identifiable by means of targeted proteomics. The use of such advanced technologies is enabling us to tackle questions and problems in a way that was not possible just a few years ago. We now have at our disposal an effective means of overcoming the problem of intratumor heterogeneity, which has limited the value of conventional biopsy approaches. As a consequence, oncology practice is about to change radically, toward truly personalized precision medicine. This book provides both clinicians and researchers with a thorough and up-to-date overview of progress in the field.
988			_aSegundosemestre_2019_Medicine
650		7	_2embne _9139108 _aBiopsia
650		7	_2embne _9139209 _aTumores
700	1		_aSchaffner, Florence _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aMerlin, Jean-Louis _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_avon Bubnoff, Nikolas _eeditor _4edt _4http://id.loc.gov/vocabulary/relators/edt
710	2		_aSpringerLink (Online service) _9106937
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9783030264383
776	0	8	_iPrinted edition: _z9783030264406
776	0	8	_iPrinted edition: _z9783030264413
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-26439-0 _zAcceso a este recurso digital (usuarios Universidad Europea de Valencia)
942			_2lcc _cLE
998			_db _feng _ggw _h0 _zSI